Beyond BRAFV600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma

被引：108

作者：

Siroy, Alan E. ^{[1
]}

Boland, Genevieve M. ^{[2
]}

Milton, Denai R. ^{[3
]}

Roszik, Jason ^{[4
]}

Frankian, Silva ^{[4
]}

Malke, Jared ^{[2
]}

Haydu, Lauren ^{[2
]}

Prieto, Victor G. ^{[1
,5
]}

Tetzlaff, Michael ^{[1
]}

Ivan, Doina ^{[1
,5
]}

Wang, Wei-Lien ^{[1
]}

Torres-Cabala, Carlos ^{[1
,5
]}

Curry, Jonathan ^{[1
]}

Roy-Chowdhuri, Sinchita ^{[1
]}

Broaddus, Russell ^{[1
]}

Rashid, Asif ^{[1
]}

Stewart, John ^{[1
]}

Gershenwald, Jeffrey E. ^{[2
,6
]}

Amaria, Rodabe N. ^{[4
]}

Patel, Sapna P. ^{[4
]}

Papadopoulos, Nicholas E. ^{[4
]}

Bedikian, Agop ^{[4
]}

Hwu, Wen-Jen ^{[4
]}

Hwu, Patrick ^{[4
]}

Diab, Adi ^{[4
]}

Woodman, Scott E. ^{[4
,7
]}

Aldape, Kenneth D. ^{[1
]}

Luthra, Rajyalakshmi ^{[8
]}

Patel, Keyur P. ^{[8
]}

Shaw, Kenna R. ^{[7
]}

Mills, Gordon B. ^{[7
]}

Mendelsohn, John ^{[9
]}

Meric-Bernstam, Funda ^{[2
,10
]}

Kim, Kevin B. ^{[4
]}

Routbort, Mark J. ^{[8
]}

Lazar, Alexander J. ^{[1
,5
]}

Davies, Michael A. ^{[4
,7
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷 / 02期

关键词：

P53; GENE; METASTATIC MELANOMA; CUTANEOUS MELANOMA; TP53; MUTATIONS; PHASE-II; BRAF; KIT; HEAD; ACTIVATION; MECHANISMS;

D O I：

10.1038/jid.2014.366

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The management of melanoma has evolved owing to improved understanding of its molecular drivers. To augment the current understanding of the prevalence, patterns, and associations of mutations in this disease, the results of clinical testing of 699 advanced melanoma patients using a pan-cancer next-generation sequencing (NGS) panel of hotspot regions in 46 genes were reviewed. Mutations were identified in 43 of the 46 genes on the panel. The most common mutations were BRAF(V600) (36%), NRAS (21%), TP53 (16%), BRAF(Non-V600) (6%), and KIT (4%). Approximately one-third of melanomas had >1 mutation detected, and the number of mutations per tumor was associated with melanoma subtype. Concurrent TP53 mutations were the most frequent events in tumors with BRAF(V600) and NRAS mutations. Melanomas with BRAF(Non-V600) mutations frequently harbored concurrent NRAS mutations (18%), which were rare in tumors with BRAF(V600) mutations (1.6%). The prevalence of BRAF(V600) and KIT mutations were significantly associated with melanoma subtypes, and BRAF(V600) and TP53 mutations were significantly associated with cutaneous primary tumor location. Multiple potential therapeutic targets were identified in metastatic unknown primary and cutaneous melanomas that lacked BRAF(V600) and NRAS mutations. These results enrich our understanding of the patterns and clinical associations of oncogenic mutations in melanoma.

引用

页码：508 / 515

页数：8

共 37 条

[1] MUTATION AND EXPRESSION OF THE P53 GENE IN HUMAN-MALIGNANT MELANOMA [J].

ALBINO, AP ;

VIDAL, MJ ;

MCNUTT, NS ;

SHEA, CR ;

PRIETO, VG ;

NANUS, DM ;

PALMER, JM ;

HAYWARD, NK .

MELANOMA RESEARCH, 1994, 4 (01) :35-45

[2] BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site [J].

Bauer, Juergen ;

Buettner, Petra ;

Murali, Rajmohan ;

Okamoto, Ichiro ;

Kolaitis, Nicholas A. ;

Landi, Maria T. ;

Scolyer, Richard A. ;

Bastian, Boris C. .

PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (02) :345-351

[3] Melanoma genome sequencing reveals frequent PREX2 mutations [J].

Berger, Michael F. ;

Hodis, Eran ;

Heffernan, Timothy P. ;

Deribe, Yonathan Lissanu ;

Lawrence, Michael S. ;

Protopopov, Alexei ;

Ivanova, Elena ;

Watson, Ian R. ;

Nickerson, Elizabeth ;

Ghosh, Papia ;

Zhang, Hailei ;

Zeid, Rhamy ;

Ren, Xiaojia ;

Cibulskis, Kristian ;

Sivachenko, Andrey Y. ;

Wagle, Nikhil ;

Sucker, Antje ;

Sougnez, Carrie ;

Onofrio, Robert ;

Ambrogio, Lauren ;

Auclair, Daniel ;

Fennell, Timothy ;

Carter, Scott L. ;

Drier, Yotam ;

Stojanov, Petar ;

Singer, Meredith A. ;

Voet, Douglas ;

Jing, Rui ;

Saksena, Gordon ;

Barretina, Jordi ;

Ramos, Alex H. ;

Pugh, Trevor J. ;

Stransky, Nicolas ;

Parkin, Melissa ;

Winckler, Wendy ;

Mahan, Scott ;

Ardlie, Kristin ;

Baldwin, Jennifer ;

Wargo, Jennifer ;

Schadendorf, Dirk ;

Meyerson, Matthew ;

Gabriel, Stacey B. ;

Golub, Todd R. ;

Wagner, Stephan N. ;

Lander, Eric S. ;

Getz, Gad ;

Chin, Lynda ;

Garraway, Levi A. .

NATURE, 2012, 485 (7399) :502-506

[4] Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy [J].

Botton, Thomas ;

Yeh, Iwei ;

Nelson, Tyrrell ;

Vemula, Swapna S. ;

Sparatta, Alyssa ;

Garrido, Maria C. ;

Allegra, Maryline ;

Rocchi, Stephane ;

Bahadoran, Philippe ;

McCalmont, Timothy H. ;

LeBoit, Philip E. ;

Burton, Elizabeth A. ;

Bollag, Gideon ;

Ballotti, Robert ;

Bastian, Boris C. .

PIGMENT CELL & MELANOMA RESEARCH, 2013, 26 (06) :845-851

[5] Clinical Characteristics and Outcomes With Specific BRAF and NRAS Mutations in Patients With Metastatic Melanoma [J].

Bucheit, Amanda D. ;

Syklawer, Erica ;

Jakob, John A. ;

Bassett, Roland L., Jr. ;

Curry, Jonathan L. ;

Gershenwald, Jeffrey E. ;

Kim, Kevin B. ;

Hwu, Patrick ;

Lazar, Alexander J. ;

Davies, Michael A. .

CANCER, 2013, 119 (21) :3821-3829

[6] KIT as a Therapeutic Target in Metastatic Melanoma [J].

Carvajal, Richard D. ;

Antonescu, Cristina R. ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Roman, Ruth-Ann ;

Teitcher, Jerrold ;

Panageas, Katherine S. ;

Busam, Klaus J. ;

Chmielowski, Bartosz ;

Lutzky, Jose ;

Pavlick, Anna C. ;

Fusco, Anne ;

Cane, Lauren ;

Takebe, Naoko ;

Vemula, Swapna ;

Bouvier, Nancy ;

Bastian, Boris C. ;

Schwartz, Gary K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2327-2334

[7] LACK OF ALLELIC DELETION AND POINT MUTATION AS MECHANISMS OF P53 ACTIVATION IN HUMAN-MALIGNANT MELANOMA [J].

CASTRESANA, JS ;

RUBIO, MP ;

VAZQUEZ, JJ ;

IDOATE, M ;

SOBER, AJ ;

SEIZINGER, BR ;

BARNHILL, RL .

INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (04) :562-565

[8] Distinct sets of genetic alterations in melanoma [J].

Curtin, JA ;

Fridlyand, J ;

Kageshita, T ;

Patel, HN ;

Busam, KJ ;

Kutzner, H ;

Cho, KH ;

Aiba, S ;

Bröcker, EB ;

LeBoit, PE ;

Pinkel, D ;

Bastian, BC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147

[9] Somatic activation of KIT in distinct subtypes of melanoma [J].

Curtin, John A. ;

Busam, Klaus ;

Pinkel, Daniel ;

Bastian, Boris C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4340-4346

[10] BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors [J].

Dahlman, Kimberly Brown ;

Xia, Junfeng ;

Hutchinson, Katherine ;

Ng, Charles ;

Hucks, Donald ;

Jia, Peilin ;

Atefi, Mohammad ;

Su, Zengliu ;

Branch, Suzanne ;

Lyle, Pamela L. ;

Hicks, Donna J. ;

Bozon, Viviana ;

Glaspy, John A. ;

Rosen, Neal ;

Solit, David B. ;

Netterville, James L. ;

Vnencak-Jones, Cindy L. ;

Sosman, Jeffrey A. ;

Ribas, Antoni ;

Zhao, Zhongming ;

Pao, William .

CANCER DISCOVERY, 2012, 2 (09) :791-797

← 1 2 3 4 →